Impact of JEV on Dengue Severity

Summary Notes on Mosquito-Borne Diseases: Dengue and Japanese Encephalitis Virus (JEV)

• Overview of the Issue:

  • Mosquito-borne diseases, particularly dengue fever, pose an increasing global health threat due to rapid urbanization and climate change.
  • Global travel has further accelerated the spread of these viruses.

• Research Findings:

  • A study has established that waning immunity against JEV may increase the severity of dengue infections.
  • JEV and dengue belong to the same virus genus, Orthoflavivirus.

• Study Context and Methodology:

  • Conducted during three dengue outbreaks in Dharan, Nepal, between 2019 and 2023.
  • Nepal's vaccination program against JE began in 2006, providing high population immunity against JEV while there was limited exposure to dengue.
  • In total, 546 dengue patients aged 15-65 were analyzed, with blood samples tested for viral serotypes, immune markers, and chymase levels.

• Key Findings:

  • Approximately 61% of participants had pre-existing antibodies neutralizing JEV.
  • Those with JEV immunity (especially at titres of 1:160) exhibited significantly higher chymase levels, an enzyme linked to severe dengue outcomes.
  • Patients with mid-range JEV antibody titres had a 3x increased risk of developing severe dengue symptoms compared to JEV-naïve patients.
  • The study's conclusions remained consistent irrespective of prior dengue exposure, emphasizing the influence of JEV immunity alone on dengue severity.
  • The presence of mid-range antibody levels, influenced by waning immunity, potentially creates a “vulnerable middle zone” where immunity is neither protective nor ineffective.

• Epidemiological Impact:

  • Rising temperatures and extended monsoons are altering dengue epidemiology, leading to larger outbreaks in regions previously experiencing sporadic cases, such as India.
  • The study suggests that countries facing similar climatic challenges need to develop effective strategies to manage dengue outbreaks.

• Implications for Vaccination:

  • Strong evidence supports the need for timely JE vaccine boosters to maintain long-lasting immunity and possibly mitigate severe dengue infections.
  • It was noted that after five years, only 63% of vaccinated individuals maintain neutralizing antibodies against JEV, highlighting the importance of booster vaccinations.

• Chymase as a Biomarker:

  • Chymase has been identified as a significant biomarker for assessing disease severity in dengue, aiding healthcare professionals in managing patient care.

• Global Health Perspective:

  • The interconnectedness of public health in a globalized context means that insights from this study may have far-reaching implications in the broader struggle against infectious diseases.

• Conclusion:

  • The study reinforces the need for integrated public health strategies to counteract the rising burden of dengue, exploit timely vaccination programs, and utilize biomarkers for effective clinical management, potentially saving countless lives.

Important Dates:

• Study conducted from 2019 to 2023
• Findings published in Science Translational Medicine on September 3, 2023.

Constitutional/Policy Around Vaccination:

• No specific constitutional references or governmental policies were mentioned, however, the findings underscore the importance of public health vaccination programs, especially in regions prone to mosquito-borne diseases.

This summary serves as a focused note on the emerging research regarding dengue and JEV, essential for understanding current public health challenges and the significance of vaccine strategies in mitigating such threats.